8 Related guidance
8.1 The Institute issued guidance on the use of glycoprotein IIb/IIIa inhibitors in September 2002:
-
National Institute for Clinical Excellence (2002) Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes. NICE Technology Appraisal Guidance No. 47. London: National Institute for Clinical Excellence.
8.2 The Institute issued guidance on the use of drugs for early thrombolysis in October 2002:
-
National Institute for Clinical Excellence (2002) Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction.NICE Technology Appraisal Guidance No. 52. London: National Institute for Clinical Excellence.
8.3 The Institute issued guidance on the use of coronary artery stents in October 2003:
-
National Institute for Clinical Excellence (2003) Guidance on the use of coronary artery stents.NICE Technology Appraisal Guidance No. 71. London: National Institute for Clinical Excellence.
8.4 The Institute issued a clinical guideline on prophylaxis for patients who have experienced an MI in April 2001:
-
National Institute for Clinical Excellence (2001) Prophylaxis for patients who have experienced a myocardial infarction. NICE Inherited Clinical Guideline A. London: National Institute for Clinical Excellence. [replaced by NICE clinical guideline 48]
8.5 The Institute issued a clinical guideline on heart failure in July 2003:
-
National Institute for Clinical Excellence (2003) Clinical Guideline on management of chronic heart failure in adults in primary and secondary care. NICE Clinical Guideline 5. London: National Institute for Clinical Excellence. [Replaced by NICE clinical guideline 108].